Alliance Wealth Advisors LLC UT Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Alliance Wealth Advisors LLC UT bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 348 shares of the biopharmaceutical company’s stock, valued at approximately $248,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. CENTRAL TRUST Co boosted its position in shares of Regeneron Pharmaceuticals by 70.7% during the 4th quarter. CENTRAL TRUST Co now owns 2,466 shares of the biopharmaceutical company’s stock worth $1,757,000 after purchasing an additional 1,021 shares during the period. River Street Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 8.0% in the fourth quarter. River Street Advisors LLC now owns 553 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 41 shares in the last quarter. Golden State Equity Partners raised its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 1,272 shares during the period. Founders Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 3.1% during the 4th quarter. Founders Capital Management LLC now owns 7,968 shares of the biopharmaceutical company’s stock valued at $5,676,000 after acquiring an additional 236 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 279.8% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 12,257 shares of the biopharmaceutical company’s stock valued at $8,731,000 after acquiring an additional 9,030 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $697.05 on Wednesday. The stock’s 50-day moving average price is $719.16 and its 200 day moving average price is $918.90. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $76.60 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Bernstein Bank lowered their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $983.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.